ADCETRIS 50 MG IV FLC
Condition : New
0
From UAE
To Malaysia
in 5-10 days
Description
Adcetris (Brentuximab Vedotin) is a targeted cancer therapy that is used in the treatment of certain types of lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It is a monoclonal antibody-drug conjugate (ADC), which combines an antibody that specifically targets CD30—a protein found on the surface of cancer cells—with a potent cytotoxic agent, monomethyl auristatin E (MMAE). This combination allows for a precise delivery of the drug to cancer cells, minimizing damage to surrounding healthy cells.
How It Works
Adcetris works by targeting and binding to the CD30 protein, which is overexpressed in certain lymphoma cells. Once it binds to CD30, the ADC is internalized by the cancer cell, releasing the cytotoxic drug MMAE directly inside the cell. MMAE disrupts the microtubules within the cancer cells, which are essential for cell division. This leads to the inhibition of cell replication and eventually induces programmed cell death (apoptosis).Mechanism of Action:
- Targeting CD30+ Cells: Brentuximab Vedotin specifically binds to the CD30 antigen, which is highly expressed in Hodgkin lymphoma and other cancers.
- Internalization: Upon binding, the drug enters the cancer cell and releases MMAE, a powerful chemotherapeutic agent.
- Inhibition of Cell Division: MMAE interferes with microtubule formation, essential for cell division, halting the proliferation of the cancer cells.
- Induction of Apoptosis: The disruption in cellular function caused by MMAE triggers apoptosis in CD30-positive cancer cells.
Side Effects
Adcetris can cause side effects, some of which can be serious. The side effects primarily stem from its ability to target rapidly dividing cells, including cancer cells and, to a lesser extent, normal cells.Common Side Effects:
- Fatigue
- Nausea and Vomiting
- Diarrhea
- Low Blood Counts: Including neutropenia, anemia, and thrombocytopenia.
- Peripheral Neuropathy: Tingling, numbness, or pain in the hands and feet.
- Fever: Due to a weakened immune system, infections are common.
- Rash: Skin irritation and rashes may occur.
Serious Side Effects:
- Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection caused by the John Cunningham virus.
- Serious Infections: Risk of severe infections, including sepsis.
- Lung Toxicity: Rarely, patients can develop interstitial lung disease or pulmonary toxicity.
- Hepatotoxicity: Liver function abnormalities, including hepatitis.
- Tumor Lysis Syndrome: A potentially life-threatening condition that occurs when cancer cells die rapidly and release their contents into the bloodstream.
Indications
Adcetris is indicated for the treatment of several types of lymphoma and conditions involving CD30-positive cancer cells.Approved Indications:
- Hodgkin Lymphoma (HL):
- For adults with classical Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after at least two prior multi-agent chemotherapy regimens.
- Systemic Anaplastic Large Cell Lymphoma (sALCL):
- For patients with systemic anaplastic large cell lymphoma after the failure of at least one prior multi-agent chemotherapy regimen.
- Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL):
- For patients with relapsed or refractory cutaneous T-cell lymphoma expressing CD30.
- Peripheral T-Cell Lymphoma (PTCL):
- In combination with chemotherapy for first-line treatment in patients with CD30-positive peripheral T-cell lymphoma.
Contraindications
Adcetris is contraindicated in certain populations due to potential adverse reactions and risks.Contraindications:
- Hypersensitivity to Brentuximab Vedotin:
- Adcetris should not be used in individuals with a known allergy to brentuximab vedotin or any of its components.
- Concomitant Use with Bleomycin:
- Use of Adcetris in combination with bleomycin is contraindicated due to an increased risk of pulmonary toxicity.
- Severe Liver Impairment:
- Patients with severe hepatic impairment should avoid Adcetris, as the drug is metabolized in the liver, and its use may result in liver toxicity.
- Pregnancy:
- Adcetris can cause harm to an unborn baby, so it is contraindicated in pregnant women unless absolutely necessary.
- Breastfeeding:
- Breastfeeding is contraindicated during treatment with Adcetris, as it is unknown whether the drug passes into breast milk and affects the infant.
Price in Different Countries
Below is a table showing the price of Adcetris 50 mg IV FLC in various countries. Prices may vary based on pharmacy, insurance coverage, and region.Country | Price (Per Vial) | Reference |
---|---|---|
United States | $10,000 – $15,000 | GoodRx |
United Kingdom | £6,000 – £7,500 | NHS |
Australia | AUD $14,000 – $16,000 | PBS Australia |
India | INR ₹750,000 – ₹900,000 | 1MG |
Canada | CAD $12,000 – $14,000 | Canada Pharmacy |
Top 5 Global Brands
Adcetris is developed by Seattle Genetics in collaboration with Takeda Oncology. It is a part of a robust global market where top pharmaceutical brands are known for cancer treatment and research.1. Seattle Genetics (Seagen)
- Seagen is the original developer of Adcetris and specializes in antibody-drug conjugates (ADCs) used for treating various cancers. It has become a leader in oncology, particularly in the development of targeted therapies.
2. Takeda Oncology
- Takeda co-markets Adcetris globally. It is a leading global biotechnology company specializing in oncology, rare diseases, and gastroenterology.
3. Roche
- Roche is one of the largest pharmaceutical companies globally and is known for its focus on cancer treatments, particularly monoclonal antibody-based therapies.
4. Bristol Myers Squibb (BMS)
- BMS is a leader in oncology and immune-oncology, focusing on developing innovative cancer therapies. It has a strong global presence and has developed a number of breakthrough cancer drugs.
5. Pfizer
- Pfizer is a major player in the oncology sector and offers a variety of cancer drugs, including targeted therapies and immunotherapies, across the globe.